AZD-0486

Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.

AstraZeneca has agreed to acquire Belgium-based EsoBiotec for up to $1 billion, with an initial payment of $425 million and additional milestone-based payments of up to $575 million.

AstraZeneca, a leading biopharmaceutical company, is making significant strides in the oncology sector with recent product approvals and promising trial results. The company's robust financial performance and strategic pipeline developments position it for continued growth, despite facing competition and regulatory challenges.

The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.

Bispecific T-cell engagers show promising real-world outcomes for relapsed/refractory large B-cell lymphoma, offering a new treatment avenue.